Today, the CSO of Ironwood Pharma (IRWD), Mark Currie, sold shares of IRWD for $3.65M.
See today’s analyst top recommended stocks >>
Based on Ironwood Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $131 million and GAAP net loss of $15.49 million. In comparison, last year the company earned revenue of $94.21 million and had a net profit of $12.09 million. Currently, Ironwood Pharma has an average volume of 1.04M.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $15.17, reflecting a 14.1% upside.
The insider sentiment on Ironwood Pharma has been positive according to 56 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F.
